Samsung Biologics has announced the expansion of its partnership with LigaChem Biosciences to advance the development of antibody-drug conjugates (ADCs).

三星生物宣布扩大与LigaChem Biosciences的合作伙伴关系，以推进抗体-药物偶联物（ADC）的开发。

LigaChem Biosciences focuses on developing ADC candidates targeting solid tumours.

LigaChem Biosciences专注于开发针对实体瘤的ADC候选药物。

The collaboration will centre on Samsung Biologics’ new ADC-dedicated facility, which features a segregated suite and a 500-litre reactor designed to support ADC development and manufacturing.

此次合作将以三星生物制品公司新的ADC专用设施为中心，该设施拥有一个独立的套件和一个500升的反应堆，旨在支持ADC的开发和制造。

This facility enhances Samsung Biologics’ existing expertise in large-scale antibody production and process engineering, offering services that span from late discovery to ADC conjugation.

该设施增强了三星生物制品（Samsung Biologics）在大规模抗体生产和工艺工程方面的现有专业知识，提供从晚期发现到ADC结合的服务。

Through this extended partnership, Samsung Biologics aims to further strengthen its capabilities in ADC development and manufacturing, ensuring high-quality therapeutic solutions are delivered to the market.

通过这种广泛的合作关系，三星生物制品旨在进一步加强其在ADC开发和制造方面的能力，确保向市场提供高质量的治疗解决方案。

LigaChem Biosciences seeks to leverage this collaboration to enhance its supply chain for ADC drugs and accelerate the progress of its pipeline, bolstering its competitiveness in the global ADC market.

LigaChem Biosciences寻求利用这一合作来增强其ADC药物的供应链，并加速其管道的进展，增强其在全球ADC市场的竞争力。

In addition to this collaboration, Samsung Biologics has been investing in innovative biotech companies through the Samsung Life Science Fund, focusing on ADC linker technologies, toolboxes, and protein engineering.

除此之外，三星生物制品公司还通过三星生命科学基金投资于创新生物技术公司，重点关注ADC连接器技术、工具箱和蛋白质工程。

These efforts underscore the company’s commitment to advancing ADC therapies and supporting clients in bringing innovative treatments to patients efficiently.

这些努力突显了该公司致力于推进ADC治疗，并支持客户有效地为患者带来创新治疗。

Source: samsungbiologics.com

来源：[UNK]samsungbiologistics.com